SCHEMBL4278003

SCHEMBL4278003

CCCCCCCCC1=C(C)OS(=O)(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
THRB P10828 1/20 0.41
CDC25A P30304 7/20 0.36
CDC25B P30305 7/20 0.36
CDC25C P30307 6/20 0.36
TYMP P19971 2/20 0.34
ALOX5 P09917 9/20 0.33
MPEG1 Q2M385 7/20 0.33
XIAP P98170 2/20 0.33
GPR84 Q9NQS5 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
PTGES O14684 1/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281978 0.83 ALDH1A1 (0.36) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL20464776 0.80 CA9 (0.32) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL4276667 0.79 CA9 (0.42) CA9
SCHEMBL4276744 0.75 CA9 (0.32) CA9
SCHEMBL5722122 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL5970520 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL4654368 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL8438882 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL8439720 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A
SCHEMBL187581 0.68 ALDH1A1 (0.51) ALDH1A1MAPTTDP1THRBCDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10251392-B2 Antimicrobial devices and compositions AVENT, INC. (US) 2019-04-09 US disclosed
US-10251392-B2 Antimicrobial devices and compositions AVENT, INC. (US) 2019-04-09 US disclosed
EP-2859961-A2 Methods and compositions for metal nanoparticle treated surfaces Avent, Inc. (US) 2015-04-15 EP disclosed
EP-1991365-B1 METHODS FOR FORMING SILVER-NANOPARTICLE TREATED SURFACES KIMBERLY CLARK CO (US) 2014-12-24 EP disclosed
US-20130122321-A1 Methods and Compositions for Metal Nanoparticle Treated Surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-05-16 US disclosed
US-20130122321-A1 Methods and Compositions for Metal Nanoparticle Treated Surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-05-16 US disclosed
US-20130122321-A1 Methods and Compositions for Metal Nanoparticle Treated Surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-05-16 US disclosed
US-8361553-B2 Methods and compositions for metal nanoparticle treated surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-01-29 US disclosed
US-8361553-B2 Methods and compositions for metal nanoparticle treated surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-01-29 US disclosed
US-8361553-B2 Methods and compositions for metal nanoparticle treated surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-01-29 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
WO-2007095058-A2 METHODS AND COMPOSITIONS FOR METAL NANOPARTICLE TREATED SURFACES ACRYMED, INC. (US) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251392-B2 Antimicrobial devices and compositions AAAS, AOC1, COL14A1 ALDH1A1 178/4885MAPT 2314/4885TDP1 4268/4885
US-20090035342-A1 Antimicrobial Devices and Compositions AAAS, AOC1, COL14A1 ALDH1A1 178/4885MAPT 2314/4885TDP1 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.